他米巴罗汀(Tamibarotene) - 药物靶点：RARα_在研适应症：急性早幼粒细胞白血病，常染色体显性多囊肾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Retinobenzoic acid、Tamibaro、Tamibarotene (JAN/INN)

+ [18]

靶点

RARα

作用方式

激动剂

作用机制

RARα激动剂(维甲酸受体α激动剂)

治疗领域

肿瘤血液及淋巴系统疾病其他疾病+ [2]

在研适应症

急性早幼粒细胞白血病常染色体显性多囊肾病

非在研适应症

晚期肝细胞癌晚期非小细胞肺癌乳腺癌+ [8]

原研机构

Nippon Shinyaku Co., Ltd.

在研机构

Toko Pharmaceutical Industrial Co. Ltd.

Rege Nephro Co. Ltd.

非在研机构

LadRx Corp.

Syros Pharmaceuticals, Inc.R&R, Inc.

+ [1]

权益机构

RaQualia Pharma, Inc.

Syros Pharmaceuticals, Inc.

QIAGEN NV

+ [2]

最高研发阶段批准上市

首次获批日期

日本 (2005-04-11),

急性早幼粒细胞白血病

最高研发阶段(中国)-

特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C22H25NO3

InChIKeyMUTNCGKQJGXKEM-UHFFFAOYSA-N

CAS号94497-51-5

关联

28

项与他米巴罗汀相关的临床试验

NCT06983210

/ Recruiting临床2期IIT

Multi-center, Open-Label, Single Arm Trial for Evaluation of the Efficacy and Safety in the First Line Combination Therapy of Gemcitabine, Cisplatin and Nivolumab With Additional Pretreatment of AM80 for Urothelial Carcinoma Patients

【Treatment of Urothelial Carcinoma】 Treatment for urothelial carcinoma includes surgery, chemotherapy (anticancer drugs), and radiation therapy. Chemotherapy is generally used when metastasis has already occurred at diagnosis and surgery is not curative (metastatic urothelial carcinoma) or when the cancer recurs after local therapy such as surgery or radiation therapy (recurrent urothelial carcinoma).
Although there are several recommended treatments for urothelial carcinoma, the options are often limited by side effects and other factors, and these treatments may not be fully effective. Therefore, the development of safer and more effective treatments is desired.
【About the Drugs to be Used in this Clinical Trial】 In this clinical trial, the investigational drug MIKE-1 will be used in combination with nivolumab plus GC (cisplatin gemcitabine), one of the recommended chemotherapy regimens, and subsequently with nivolumab monotherapy for patients with unresectable metastatic or recurrent urothelial cancer. Nivolumab, cisplatin, and gemcitabine are injectable (intravenous infusion), while MIKE-1 is oral.
【Purpose of the Clinical Trial】 The purpose of this clinical trial is to evaluate the efficacy (how much the cancer shrinks or slows down) and safety of the investigational drug MIKE-1 in combination with nivolumab and gemcitabine and cisplatin therapy in patients with untreated unresectable or recurrent urothelial cancer.

开始日期2025-05-01

申办/合作机构

Nagoya University

[+1]

NCT06289998

/ Active, not recruiting临床2期

Phase IIa Clinical Trial of Tamibarotene in Patients With Autosomal Dominant Polycystic Kidney Disease

Clinical trial of tamibarotene in patients with Autosomal Dominant Polycystic Kidney Disease

开始日期2023-12-22

申办/合作机构

Rege Nephro Co. Ltd.

JPRN-jRCT2011230055

/ Suspended临床2期IIT

Phase IIa clinical trial of tamibarotene in patients with Autosomal Dominant Polycystic Kidney Disease

开始日期2023-12-12

申办/合作机构-

100 项与他米巴罗汀相关的临床结果

登录后查看更多信息

100 项与他米巴罗汀相关的转化医学

登录后查看更多信息

100 项与他米巴罗汀相关的专利（医药）

登录后查看更多信息

490

项与他米巴罗汀相关的文献（医药）

2025-12-31·AUTOIMMUNITY

Deciphering distinct pathogenic mechanisms of ankylosing spondylitis and systemic sclerosis via shared biomarkers ZSWIM6 and CCL3L3: Insights from an integrative bioinformatics approach

Article

作者: Zhou, Chenxing ; Chen, Jiarui ; Zhan, Xinli ; Xue, Jiang ; Shi, Jianjun ; Zhou, Zhongxian ; Yang, Renbang ; Huang, Liangyu ; Huang, Chengqian ; Liu, Chong ; Chen, Tianyou ; Feng, Sitan ; Huang, Jieping ; Wu, Shaofeng ; Zhu, Jichong

Ankylosing Spondylitis (AS) and Systemic Sclerosis (SSc) are both autoimmune diseases, albeit with distinct anatomical targets. AS primarily affects the spine and sacroiliac joints, triggering inflammation and eventual fusion of the vertebrae. SSc predominantly impacts the skin and connective tissues, leading to skin fibrosis, thickening, and potential damage to vital organs such as the lungs, heart, and kidneys. Despite their differing anatomical manifestations, inflammation serves as a pivotal factor in both conditions. Exploring the causes of the different pathogenesis of inflammation in AS and SSc could provide new insights into their treatment. We selected RNA-seq profiles of peripheral blood mononuclear cells (PBMCs) from the GEO datasets GSE73754 and GSE19617. DEGs were identified using the Limma R package with an adjusted p-value cutoff of < 0.05. Gene Ontology pathway analysis, SVM recursive feature elimination, and Gene Set Enrichment Analysis (GSEA) were conducted to analyze the DEGs. CIBERSORT was applied to estimate immune cell composition and its correlation with hub genes. Single-cell RNA sequencing data from peripheral blood mononuclear cells in the GSE194315 dataset were included to support differential expression analysis and biomarker identification. Additionally, single-cell RNA sequencing data from bone marrow blood samples were utilized to further validate these findings, offering complementary insights into biomarker expression across distinct sample types. A total of 762 DEGs were identified between AS patients and controls, and 441 DEGs between SSc patients and controls. Both conditions showed enrichment in the Natural killer cell mediated cytotoxicity pathway. ZSWIM6 and CCL3L3 were identified as potential biomarkers in AS and SSc, with significant diagnostic capabilities demonstrated by ROC analysis. Correlation analysis revealed associations between these biomarkers and specific immune cell types. The study utilizing ZSWIM6 and CCL3L3 as potential biomarkers provides deep insights into the distinct molecular mechanisms of SSc and AS. These findings lay the foundation for future research on targeted therapies and enhance our understanding of immune cell interactions in these autoimmune diseases.

2025-05-02·INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

Retinoic Acid Receptor Alpha- and Beta-Mediated Signaling Regulates Conjunctival Epithelial Cell Keratinization

Article

作者: Naito, Yuji ; Kinoshita, Shigeru ; Yokoi, Norihiko ; Yokoo, Seiichi ; Sotozono, Chie ; Yoshioka, Hokoru ; Mizushima, Katsura ; Ueta, Mayumi

Purpose:

Keratinization of the mucosal epithelia develops in severe ocular surface disorders, causing severe visual loss. This study elucidates the molecular mechanisms of keratinization in conjunctival epithelial cells (CjECs) and investigates the involvement of the vitamin A pathway.

Methods:

Keratinized conjunctival epithelial sheets were generated by a closed system culture of human CjECs and confirmed by immunostaining. Comprehensive gene expression analysis and quantitative real-time PCR (qRT-PCR) were used to examine whether the cells could be used as an in vitro keratinization model. Moreover, immunostaining and qRT-PCR were used to examine alterations of vitamin A pathway-related genes in the cells and also the effect of adding all-trans retinoic acid (ATRA) and retinoic acid receptor alpha/beta (RARA/RARB) agonist Am80. Knockdown of RARA or RARB was also performed using transfection of small interfering RNA to identify receptors for retinoic acid.

Results:

Immunostaining revealed that CjECs cultured in a closed system had increased expression of keratinization markers. Comprehensive gene expression analysis and qRT-PCR revealed expression changes in vitamin A pathway genes, in addition to keratinization. In the closed system culture, immunostaining revealed that conjunctival epithelial keratinization was suppressed or partially ameliorated by ATRA or Am80, and qRT-PCR revealed that vitamin A pathway-related genes were significantly altered. Moreover, knockdown of RARA or RARB induced an increase in keratinization marker involucrin.

Conclusions:

Keratinization of CjECs involves RARA or RARB-mediated pathways, and ATRA and Am80 alter the expression of vitamin A pathway gene and suppress keratinization.

2025-04-01·BIOCHEMICAL PHARMACOLOGY

Tamibarotene directly targets the NACHT domain of NLRP3 to alleviate acute myocardial infarction

Article

作者: Huang, Junjun ; Wang, Yunjing ; Ye, Weijun ; Xiao, Qing ; Xu, Fengdan ; Chen, Xiuhui ; Long, Rui ; Zhang, Xiaofeng ; Dou, Huaqian ; Zheng, Yutong ; Zhang, Zhe

The aberrant activation of the nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing protein 3 (NLRP3) inflammasome has been implicated in the exacerbation of myocardial damage and the subsequent development of heart failure following myocardial infarction (MI). Inhibiting NLRP3 inflammasome activation offers a promising therapeutic strategy for mitigating MI-related injury, although no NLRP3 inhibitors have received Food and Drug administration (FDA) approval to date. To identify novel NLRP3 inflammasome inhibitors through the repurposing of FDA-approved drugs, Tamibarotene emerged as a potent inhibitor with a favorable safety profile. Mechanistically, Tamibarotene inhibits NLRP3 inflammasome activation independently of retinoic acid receptor activation, binding to Phe410 and Ile417 within the nucleotide-binding and oligomerization (NACHT) domain in an ATPase activity-dependent manner. This interaction further inhibits the assembly of the NLRP3 inflammasome. In a murine model of MI, Tamibarotene significantly reduced myocardial damage and improved cardiac function by inhibiting NLRP3 inflammasome activation. In summary, NLRP3 has been identified as a direct target of Tamibarotene for myocardial repair following MI, indicating that Tamibarotene could serve as a potential precursor for the development of innovative NLRP3 inhibitors.

102

项与他米巴罗汀相关的新闻（医药）

2025-04-17

·Endpoints

Bayer opens $44M US expansion; Meribel CDMO launches in Europe

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Bayer has opened its $44 million 70,000-square-foot expansion at its Myerstown, PA, facility, the company said Wednesday. The site manufactures products for Bayer’s consumer health business. A new mid-size CDMO called Meribel Pharma Solutions launched on Tuesday, according to a release on the same day. The new company will operate out of 10 manufacturing sites, seven of which it bought from Recipharm last year, and three research and development facilities in Europe. Ginkgo Bioworks has secured a $29 million two-year contract with Advanced Research Projects Agency for Health along with other companies including Tritica Biosciences, US Pharmacopeia, On Demand Pharmaceuticals and Isolere Bio by Donaldson. The project is intended to establish a new manufacturing process for APIs using wheat germ cell-free expression tech, according to a release on April 10. CDMO Chime Biologics has partnered with Polpharma Biologics to manufacture an unnamed biosimilar, according to a Wednesday release. Cell therapy biotech Atelerix has teamed up with China-based logistics company MineBio, which will distribute Atelerix’s products in China, the companies said Tuesday. FesariusTherapeutics has partnered with Regenity Biosciences who will manufacture FesariusTherapeutics’ collagen-based dermal regeneration templates used to treat patients with wounds, according to a Thursday press release. Renal disease-focused Rege Nephro has acquired clinical and non-clinical assets related to the chemical tamibarotene from Syros Pharmaceuticals, the company said Tuesday. The deal closed on Feb. 26. Clinical-stage INmune Bio has partnered with UK-based CGT Catapult to establish commercial manufacturing for its cell therapy technologies, according to a Monday release. Kyowa Kirin has completed the construction of its new 16.8 billion Japanese yen ($118 million) drug substance manufacturing site in Takasaki, Japan, the company said on Apr. 11.

细胞疗法

2025-04-15

·PRNewswire

Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials

KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters: Boston, MA; NASDAQ:SYRS), through a mutual agreement. The acquisition was completed on February 26, 2025. Tamibarotene (RN-014) is a retinoic acid receptor agonist for which Rege Nephro is currently conducting a Phase 2 clinical trial in Japan in autosomal dominant polycystic kidney disease (ADPKD). Rege Nephro expects to initiate clinical trials in the United States, after confirming the efficacy and safety in Japan. Syros Pharmaceuticals has previously carried out a Phase 3 clinical trial of Tamibarotene for indications including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This acquisition, encompassing their clinical and non-clinical data including human safety study for New Drug Application (NDA), contracts with a contract manufacturing organization (CMO), and Tamibarotene active pharmaceutical ingredient (API) and drug products, is expected to enhance Rege Nephro's capabilities and streamline operations for its clinical trial operations in the United States. About Rege Nephro: Rege Nephro, founded in 2019, is a clinical-stage biotech company leveraging technology based on research of Prof. Kenji Osafune, deputy director of the Center for iPS Cell Research and Application (CiRA), Kyoto University. The company is developing therapeutics and cell therapy for diseases related to the kidneys, liver, and pancreas. For more information, please visit . About RN-014: RN-014 is a therapeutic candidate for autosomal dominant polycystic kidney disease (ADPKD). It is a retinoic acid receptor (RAR) agonist expected to suppress cyst formation and improve renal function. Rege Nephro initiated a Phase 2 clinical trial in December 2023, and enrollment for the second stage has now been completed. To date, no significant safety concerns have arisen and preliminary efficacy has been demonstrated. SOURCE Rege Nephro Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期细胞疗法并购临床3期临床1期

2025-03-05

·抗体圈

突发！Syros 折戟 Ⅲ 期临床，黯然退市背后藏着啥？

近日，一则消息在生物医药行业掀起惊涛骇浪：Syros Pharmaceuticals 公司宣布，或将从纳斯达克交易市场退市，并注销其发行普通股。Syros 预计于 3 月 10 日向美国证券交易委员会提交材料，3 月 20 日正式摘牌。这一决策瞬间成为行业焦点，引发了无数从业者和投资者的关注与思考。公司沉浮：曾经的希望与如今的困境 Syros Pharmaceuticals 成立于 2011 年，由知名风险投资公司 Flagship Pioneering 孵化，专注于基因调控疗法的开发。这本是一家怀揣着创新梦想，致力于攻克血液肿瘤难题的企业，2022 年收购 TYME 公司后在纳斯达克交易市场上市，也曾在资本市场上崭露头角。然而，辉煌的背后，Syros 的运营处境却一直十分堪忧。多年来，公司一直处于亏损状态，早早丧失了融资能力，只能借助外部金融贷款勉强维持运营。这就如同在波涛汹涌的大海中，一艘失去动力的船，只能依靠偶尔的救援艰难前行。折戟临床：核心管线的失败之路 Syros 将所有的希望都寄托在了核心管线 tamibarotene 上。tamibarotene 并非 Syros 自主研发的新药，它最早由日本 Nippon Shinyaku 公司开发，2005 年 6 月在日本被批准上市用于治疗急性早幼粒细胞白血病。但 Syros 认为其在 RARA 过表达的高风险 MDS 和 RARA 过表达 AML 两个适应症中具备巨大的治疗潜力。然而，现实却残酷地打破了 Syros 的幻想。在针对 40 名新诊断 RARA 过表达 AML 患者的 SELECT-AML-1 试验中，Tamibarotene 三联疗法组患者的 CR/CRi 率不及对照组（65% VS 70%）。公司经过评估，认为在最终分析中，Tamibarotene 三联疗法组显示出优势的可能性不大。2024 年 8 月，Syros 无奈宣布停止 SELECT-AML-1 的患者招募。这一消息犹如一颗重磅炸弹，使得公司股价暴跌 70%，市场信心遭受重创。但厄运并未就此停止。2024 年 11 月，Tamibarotene 治疗新诊断 RARA 基因过表达高危骨髓增生异常综合征（HR-MDS）患者的 III 期临床 SELECT-MDS-1 再次传来噩耗，与对照组相比，Tamibarotene + Azacitidine 联合疗法未能显著提高某些 MDS 患者的完全缓解率，未能达到主要终点目标。公司首席执行官 Conley Chee 表示对这一结果深感失望，公司也不得不停止 SELECT-MDS-1 临床试验。这一打击让市场信心彻底坠入谷底，公司股价急剧下跌，跌幅高达 92%。违约危机：贷款协议背后的 “致命枷锁” 为了推进 tamibarotene 的研发，Syros 在 2020 年与 Oxford Finance LLC 签订了一项贷款和担保协议，获得了 4000 万美元的贷款。这本是一场 “及时雨”，但在 2022 年修订的贷款协议中，Oxford Finance 追加了一系列违约条款，将 tamibarotene 的命运与这笔贷款协议紧紧绑定。若 SELECT-MDS-1 未达到临床主要终点、SELECT-MDS-1 因安全性原因终止，以及未能在 2026 年 5 月 31 日前获得 FDA 批准，都构成与 Oxford Finance LLC 贷款协议的违约。如今，SELECT-MDS-1 临床失败，无疑触发了这一 “定时炸弹”。Syros 的还款日期本就临近，这次贷款违约让公司的还款压力如山般沉重，财务状况更是雪上加霜，犹如在伤口上撒盐，让公司陷入了绝境。行业警钟：Syros 退市带来的启示 Syros 的黯然退市，为整个生物医药行业敲响了一记沉重的警钟。生物医药研发是一个高投入、高风险、长周期的领域，每一款药物的诞生都像是一场艰难的马拉松，需要经过无数次的临床试验和严格审批。任何一个环节的失误，都可能让前期投入的大量人力、物力和财力付诸东流。对于药企来说，不能将所有的鸡蛋放在一个篮子里，在追求创新疗法的同时，必须谨慎评估研发风险，合理规划资金与资源。要建立多元化的研发管线，降低对单一产品的依赖，避免因一款药物的失败而使公司陷入万劫不复之地。而对于投资者而言，这也是一次深刻的教训。在生物医药领域投资时，不能仅仅被企业描绘的美好研发前景所迷惑，要更加谨慎地评估项目的可行性和风险。需要深入研究企业的研发实力、临床数据以及财务状况，做出理性的投资决策。 Syros 的故事虽然落幕，但它留下的思考和警示，将长久地影响着生物医药行业。希望未来，行业能够从这次事件中吸取教训，在创新研发的道路上更加稳健地前行，让更多真正有效的药物能够造福患者，也让生物医药行业能够健康、持续地发展。识别微信二维码，添加抗体圈小编，符合条件者即可加入抗体圈微信群！请注明：姓名+研究方向！本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

临床3期并购引进/卖出临床2期临床失败

100 项与他米巴罗汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01418	他米巴罗汀	L01X	DB04942

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
急性早幼粒细胞白血病	日本	Toko Pharmaceutical Industrial Co. Ltd.	2005-04-11

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
RARα阳性骨髓增生异常综合征	临床3期	美国	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	奥地利	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	比利时	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	加拿大	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	捷克	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	法国	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	德国	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	匈牙利	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	以色列	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	意大利	Syros Pharmaceuticals, Inc.	2021-02-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04797780 (SELECT-MDS-1, CTgov)	临床3期	RARα阳性骨髓增生异常综合征	246	Tamibarotene+Azacitidine (Tamibarotene + Azacitidine)	積繭膚膚憲繭齋鏇網襯 = 鑰鹹積膚糧遞艱齋鹽觸衊鏇憲壓鹽壓鹽鬱膚憲 (遞築齋遞鹽顧衊鹽淵鬱, 繭淵憲築築壓膚鹽簾廠 ~ 蓋窪獵願窪願窪網網簾) 更多	-	2025-04-10
				Placebo+Azacitidine (Tamibarotene Matched Placebo + Azacitidine)	積繭膚膚憲繭齋鏇網襯 = 膚製襯艱繭積網壓夢繭衊鏇憲壓鹽壓鹽鬱膚憲 (遞築齋遞鹽顧衊鹽淵鬱, 窪範網餘淵餘壓獵構艱 ~ 範窪遞壓壓壓餘顧顧鏇) 更多
NCT04905407 (AML-347 SELECT-AML-1 \| SELECT AML-1 \| SELECT-AML-1, CTgov)	临床2期	RARA阳性急性髓性白血病	66	Tamibarotene+Venetoclax+Azacitidine (Part 1: Tamibarotene/Venetoclax/Azacitidine)	鏇憲鏇艱膚憲憲壓鑰糧 = 鑰淵積顧淵範蓋顧艱膚鹽範餘窪憲網齋襯構憲 (願淵夢觸鑰壓範製糧蓋, 顧夢憲艱艱淵鬱醖蓋憲 ~ 憲構襯廠齋壓鹽鑰襯簾) 更多	-	2025-02-24
				Tamibarotene+Venetoclax+Azacitidine (Part 2: Tamibarotene/Venetoclax/Azacitidine)	築鑰蓋餘蓋範遞觸夢顧 = 築淵夢憲鑰獵鏇選選觸選衊繭願醖鬱願簾廠簾 (窪齋鹽積艱願鬱艱鏇製, 獵範築網鹹窪齋繭築製 ~ 範顧鹽鏇積齋範網選築) 更多
NCT02807558 (CTgov)	临床2期	急性髓性白血病 \| 骨髓增生异常综合征	155	Tamibarotene (R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy)	餘醖築餘淵顧顧願願齋 = 獵壓齋壓廠醖鏇衊觸選顧廠鑰鏇壓遞艱鹹衊醖 (壓廠範遞網齋繭淵獵壓, 膚構膚觸鹹餘觸鏇範願 ~ 衊壓廠積鹹鹹艱鬱醖蓋) 更多	-	2024-12-13
				Tamibarotene (Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy)	餘醖築餘淵顧顧願願齋 = 廠簾淵憲淵廠鬱鬱願構顧廠鑰鏇壓遞艱鹹衊醖 (壓廠範遞網齋繭淵獵壓, 鑰積繭鹽願廠鹽艱簾鏇 ~ 醖範窪鏇壓鹹獵遞簾選) 更多
NCT04797780 (SELECT-MDS-1, Company_Website) 人工标引	临床3期	高危骨髓增生异常综合征	190	Tamibarotene in combination with azacitidine	觸顧窪壓鹽衊遞選繭選(淵遞遞鏇壓網選衊艱遞) = 鹽遞築廠積願鬱壓襯積遞餘壓顧糧襯淵廠獵窪 (窪壓鏇選繭衊願鏇製繭, 16.7 ~ 32.2) 未达到	不佳	2024-11-12
				Placebo and azacitidine	觸顧窪壓鹽衊遞選繭選(淵遞遞鏇壓網選衊艱遞) = 網範壓衊淵築繭鹽襯鑰遞餘壓顧糧襯淵廠獵窪 (窪壓鏇選繭衊願鏇製繭, 10.1 ~ 30.5) 未达到
NCT04905407 (AML-347 SELECT-AML-1, SOHO2024)	临床2期	RARA阳性急性髓性白血病 RARA overexpression	80	Tamibarotene 6 mg PO BID + Venetoclax-Azacitidine	網艱顧觸願襯夢遞繭顧(獵積鏇夢鑰構鬱觸繭壓) = 糧廠鑰願鹽壓簾鹹簾網鬱鑰襯窪鬱願膚壓獵膚 (鏇築醖壓壓餘鏇構齋鹹 ) 更多	积极	2024-09-04
				Venetoclax-Azacitidine	網艱顧觸願襯夢遞繭顧(獵積鏇夢鑰構鬱觸繭壓) = 鏇憲鬱鏇憲範網積壓構鬱鑰襯窪鬱願膚壓獵膚 (鏇築醖壓壓餘鏇構齋鹹 ) 更多
NCT04905407 (SELECT-AML-1, NEWS) 人工标引	临床2期	RARA阳性急性髓性白血病 RARA	19	tamibarotene+venetoclax+azacitidine	窪鑰糧鏇觸衊衊齋鹹構(齋壓鑰壓淵蓋窪鬱獵鑰) = 鹽鏇願壓膚獵蓋鬱顧糧鏇壓鬱鏇憲範鹹窪簾衊 (醖積繭淵願艱鹹醖鹽鹽 ) 更多	积极	2023-12-07
				venetoclax+azacitidin	窪鑰糧鏇觸衊衊齋鹹構(齋壓鑰壓淵蓋窪鬱獵鑰) = 襯蓋鑰鏇鹹範簾鹽鏇選鏇壓鬱鏇憲範鹹窪簾衊 (醖積繭淵願艱鹹醖鹽鹽 ) 更多
NCT02807558 (Pubmed)	临床2期	急性髓性白血病	51	Tamibarotene plus azacitidine	淵顧網齋鏇範憲築範鬱(齋衊繭鬱鏇糧積獵範窪) = hematologic AEs were comparable to single agent azacitidine, demonstrating that there was no additional myelosuppression when tamibarotene was combined with azacitidine 膚鬱鬱觸遞鑰憲窪築選 (範遞膚壓壓鏇淵繭鏇鏇 ) 更多	-	2022-12-07
NCT04905407 (SELECT-AML-1, ASH 12022 \| ASH 22022) 人工标引	临床2期	RARA阳性急性髓性白血病一线 RARA	6	Venetoclax+Azacitidine+Tamibarotene	壓鹹壓網網憲簾窪願壓(願糧醖齋鑰鬱齋積構選) = occurring in more than one patient was febrile neutropenia 顧鑰壓顧繭衊選構夢夢 (鹹鏇壓糧選壓蓋衊衊淵 ) 更多	积极	2022-11-15
				Venetoclax+Azacitidine
NCT04905407 (SELECT-AML-1, SOHO2022)	临床2期	RARA阳性急性髓性白血病 RARA-positive	-	Tamibarotene/venetoclax/azacitidine	鏇憲餘襯築醖艱遞構觸(夢淵構夢製選獵選膚糧) = 壓窪窪蓋築艱網網製夢範製簾艱構觸範憲網醖 (網鏇積蓋構網顧選夢鬱 )	-	2022-10-01
NCT02807558 (ASH 12020 \| ASH 22020) 人工标引	临床2期	复发性急性髓细胞白血病 RARA Positive	28	Azacitidine+SY-1425	窪顧願鹽製醖積顧餘遞(遞艱醖製網願淵蓋鹽鹹) = 選鏇製鏇蓋憲鹹構廠繭繭範觸構衊製廠繭繭繭 (襯窪構淵網憲壓衊夢繭 ) 更多	积极	2020-11-05